- Trial phase
- Phase 2 completed / Phase 3-ready
- Time to market
- ABO-801 is Phase 3-ready but no Phase 3 trial has been announced. Assuming a typical 1-2 year Phase 3 program plus FDA review, potential approval would be at least 3-4 years away, though the Fast Track designation could accelerate the timeline.
- Why 4/10
- ABO-801 was just acquired on November 9, 2026 and is Phase 3-ready, but no Phase 3 trial start date or PDUFA has been announced. The next drug-specific catalyst (Phase 3 initiation or data readout) is likely more than 12 months away. The stock's primary value driver remains the approved, commercial-stage gene therapy ZEVASKYN. ABO-801 is a pipeline expansion asset with no near-term binary catalyst, capping the impact score at 4.
Watch for the initiation of a Phase 3 trial for ABO-801 in eosinophilic esophagitis, which would be the next meaningful drug-specific catalyst. Near term, monitor the activist investor situation (James Russell's 6.1% stake and board-change demands) and the registration statement filing for the PIPE shares, as these could drive further volatility. The Q3 earnings beat and ZEVASKYN revenue growth ($13.5M, up 18% QoQ) provide a commercial foundation, but the dilutive financing and activist pressure create a mixed setup.
Price Chart
Executive Summary
ABO-801 (formerly APT-1011) is a Phase 3-ready, once-daily oral therapy for eosinophilic esophagitis (EoE) that Abeona Therapeutics acquired from Ellodi Pharmaceuticals on November 9, 2026 for $20M in stock plus up to $60M in milestones and royalties. The deal was announced concurrently with a $30M PIPE financing at $3.75/share and Q3 2026 earnings showing ZEVASKYN revenue of $13.5M (up 18% QoQ). ABO-801 has FDA Orphan Drug and Fast Track designations and demonstrated positive Phase 2 data (FLUTE-2 trial) showing higher rates of complete symptomatic response at 12 weeks versus placebo. The stock traded down ~16% in pre-market on the dilutive financing and activist investor pressure. ABO-801 diversifies Abeona beyond its approved gene therapy ZEVASKYN but has no near-term binary catalyst, as a Phase 3 trial has not yet been initiated.
How It Works
ABO-801 is a once-daily, oral therapy for eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. It is designed to be swallowed as a liquid, allowing it to coat the esophagus directly and reduce the allergic-type inflammation that causes difficulty swallowing and other symptoms. The drug has completed Phase 2 testing and is ready for Phase 3 trials.
Trial Status
ABO-801 (as APT-1011) completed the Phase 2 FLUTE-2 trial, which showed a higher rate of complete symptomatic response at 12 weeks compared to placebo, with improvements maintained up to 38 weeks. The drug has not yet initiated a Phase 3 trial under Abeona's sponsorship.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 3 trial for ABO-801 in eosinophilic esophagitis (date TBD)
- Registration statement filing for PIPE shares (due within 15 days of November 9, 2026)
- Activist investor James Russell potential proxy contest or board changes
- ZEVASKYN quarterly revenue growth trajectory and Qualified Treatment Center expansion
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Abeona Therapeutics Inc. Press Release ABEO ·Originating report